Pre-Clinical and Clinical Development of a Next-Generation mRNA COVID-19 Vaccine

Time: 11:45 am
day: Day One Morning


  • Preliminary preclinical results for second generation vaccines designed with improved anti-viral immunogenicity exhibited cross neutralizationagainst alpha, beta, gamma and delta circulating viral variants in mice and non-human primates
  • Rhesus macaque immunogenicity studies showed high neutralizing antibody titers after two prime injections 28 days apart
  • A further increase in neutralizing antibody titers were observed with a boost injection 120 days after the second prime injection